Weiss Ratings Reaffirms Sell (E+) Rating for Prime Medicine (NASDAQ:PRME)

Key Points

• Weiss Ratings has reaffirmed a "sell (E+)" rating for Prime Medicine (NASDAQ:PRME), indicating ongoing concerns about the stock's performance.
• In contrast, Wall Street Zen has upgraded its rating for Prime Medicine from "sell" to "hold," suggesting some analysts see potential for stability.
• As of Friday, Prime Medicine shares opened at $5.33, with a market cap of $717.26 million and a 12-month price range between $1.11 and $6.94.

Prime Medicine (NASDAQ:PRME - Get Free Report)'s stock had its "sell (e+)" rating restated by analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Prime Medicine from a "sell" rating to a "hold" rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Prime Medicine has a consensus rating of "Sell".

Prime Medicine Price Performance

Shares of PRME stock opened at $5.33 on Friday. The firm has a market cap of $717.26 million, a P/E ratio of -3.42 and a beta of 2.65. Prime Medicine has a 12 month low of $1.11 and a 12 month high of $6.94.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.